TickerFacts.

Interpace Biosciences, Inc. (IDXG): Cash & Equivalents

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2021-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$2.50M
As of 2025-12-31
$2.69M
As of 2026-06-30
-19.6%
3-year compound annual growth
$64.34M2010-12-31: $62.71M2011-12-31: $64.34M2012-12-31: $52.78M2013-12-31: $45.64M2014-12-31: $23.11M2015-12-31: $8.31M2016-12-31: $602.0K2017-12-31: $15.20M2018-12-31: $6.07M2019-12-31: $2.32M2020-12-31: $2.77M2021-12-31: $2.67M2022-12-31: $4.83M2023-03-31: $5.60M2023-06-30: $5.08M2023-12-31: $3.50M2024-03-31: $2.81M2024-06-30: $2.02M2024-09-30: $2.11M2024-12-31: $1.46M2025-12-31: $2.50M$2.50M
2010-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$2.50M+71.5%2026-03-30, Balance as of period end
2024-12-31$1.46Mn/a2026-03-30, Balance as of period end
2024-09-30$2.11Mn/a2025-03-31, Balance as of period end
2024-06-30$2.02Mn/a2025-03-31, Balance as of period end
2024-03-31$2.81Mn/a2025-03-31, Balance as of period end
2023-12-31$3.50Mn/a2025-03-31, Balance as of period end
2023-06-30$5.08Mn/a2025-03-31, Balance as of period end
2023-03-31$5.60Mn/a2025-03-31, Balance as of period end
2022-12-31$4.83M+80.7%2024-04-01, Balance as of period end
2021-12-31$2.67Mn/c2023-03-27, Balance as of period end
2020-12-31$2.77M+19.4%2022-03-31, Balance as of period end
2019-12-31$2.32M-61.8%2021-04-01, Balance as of period end
2018-12-31$6.07M-60.1%2021-01-19, Balance as of period end
2017-12-31$15.20Mn/m2019-03-21, Balance as of period end
2016-12-31$602.0K-92.8%2018-03-23, Balance as of period end
2015-12-31$8.31M-64.0%2017-03-31, Balance as of period end
2014-12-31$23.11M-49.4%2016-03-30, Balance as of period end
2013-12-31$45.64M-13.5%2015-03-05, Balance as of period end
2012-12-31$52.78M-18.0%2014-03-06, Balance as of period end
2011-12-31$64.34M+2.6%2013-03-15, Balance as of period end
2010-12-31$62.71Mn/a2012-03-09, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Surgical & Medical Instruments & Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Interpace Biosciences, Inc. (IDXG)2025-12-31$2.50M+71.5%
Utah Medical Products Inc (UTMD)2025-12-31$85.76M+3.4%
Retractable Technologies Inc (RVP)2025-12-31$2.59M-38.9%
Cytosorbents Corp (CTSO)2025-12-31$6.25M+90.5%
ClearPoint Neuro, Inc. (CLPT)2025-12-31$45.92M+128.4%
KORU Medical Systems, Inc. (KRMD)2025-12-31$8.87M-7.4%
SS Innovations International, Inc. (SSII)2025-12-31$3.21M+587.3%
SANUWAVE Health, Inc. (SNWV)2025-12-31$11.96M+16.8%
Orchestra BioMed Holdings, Inc. (OBIO)2025-12-31$34.69M+55.8%

Compare IDXG, UTMD, RVP, CTSO side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗